

WHO/V&B/03.06
ORIGINAL: ENGLISH

Report of the Strategic Advisory Group of Experts (SAGE)

Geneva, 14–15 June 2002



Vaccines and Biologicals

World Health Organization

Report of the Strategic Advisory Group of Experts (SAGE)

Geneva, 14–15 June 2002



Vaccines and Biologicals

World Health Organization

**The Department of Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this publication possible.**

This publication was produced by the
Department of Vaccines and Biologicals

Ordering code: WHO/V&B/ 03.06
Printed: April 2003

This publication is available on the Internet at:
www.who.int/vaccines-documents/

Copies may be requested from:
World Health Organization
Department of Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland
• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

Contents

<i>Abbreviations</i>	<i>v</i>
<i>Executive summary</i>	<i>vii</i>
1. Plenary opening session	1
1.1 Introduction.....	1
1.2 The Strategic Plan.....	2
1.3 WHO Initiative for Vaccine Research: structure and strategy	4
1.4 Report of the Technical Consultative Group on the Global Eradication of Poliomyelitis	5
1.5 Report from the Third Global Vaccine Research Forum	8
1.6 GAVI: status and WHO role	8
2. Innovation	13
2.1 The Initiative for Vaccine Research	13
2.2 Prioritization of vaccines	15
2.3 Update on thiomersal and vaccines	19
2.4 Policy issues in new vaccine introduction: Hib and hepatitis B	21
2.5 Update on vaccine security	25
2.6 Update on activities relating to meningitis.....	27
3. Immunization systems	34
3.1 Report of the Steering Committee of the priority project on Immunization Safety	34
3.2 New vaccine introduction in Vaccine Fund-eligible countries	39
3.3 Strengthening routine immunization at national, district and subdistrict levels.....	42
4. Accelerated disease control	51
4.1 Post-certification immunization policy	51
4.2 Progress report on maternal and neonatal tetanus elimination	55
4.3 Yellow fever: a targeted approach for prevention	58
4.4 Vaccine supply for disease control initiatives	62
4.5 A sustainable approach to measles control	66
5. Plenary closing session	73
5.1 Presentations by subgroups	73
5.2 Future SAGE meetings	73
5.3 Closing remarks	73
Annex 1: List of participants	74

Abbreviations

AD	auto-disable (syringes)
ADC	accelerated disease control
AEFIs	adverse events following immunization
AFP	acute flaccid paralysis
CDC	Centers for Disease Control and Prevention (USA)
CDS	Communicable Diseases cluster (WHO)
CSR	Department of Communicable Disease Surveillance and Response
CRS	congenital rubella syndrome
cVDPV	circulating vaccine-derived viruses
DTP	diphtheria–tetanus–pertussis (vaccine)
EPI	Expanded Programme on Immunization
ETEC	enterotoxigenic <i>Escherichia coli</i>
GAVI	Global Alliance for Vaccines and Immunization
GVF	Global Vaccine Fund
HBV	hepatitis B virus
HepB	hepatitis B vaccine
Hib	<i>Haemophilus influenzae</i> type b
HTP	Health Technology and Pharmaceuticals cluster (WHO)
ICCs	interagency coordinating committees
IPV	inactivated polio vaccine
iVDPV	vaccine-derived poliovirus associated with immunodeficiency
IVI	International Vaccine Institute
IVR	initiative for vaccine research
JE	Japanese encephalitis
MMR	measles–mumps–rubella (vaccine)
MNT	maternal and neonatal tetanus
MR	measles-rubella
MVP	Meningitis Vaccine Project
NIDs	national immunization days

NRA	national regulatory authority
OPV	oral polio vaccine
PAHO	Pan American Health Organization
PATH	Program for Appropriate Technology in Health
PEI	Polio Eradication Initiative
R&D	research and development
SAGE	Strategic Advisory Group of Experts
SIAs	supplementary immunization activities
SNIDs	subnational immunization days
TAGs	technical advisory groups
TDR	Special Programme for Research and Training in Tropical Diseases
TCG	Technical Consultative Group
Td	tetanus–diphtheria toxoid
TT	tetanus toxoid
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNFPA	United Nations Population Fund
VAPP	vaccine-associated polio
V&B	Department of Vaccines and Biologicals (WHO)
VDPV	vaccine-derived poliovirus
WHA	World Health Assembly
WHO	World Health Organization
YF	yellow fever

Abbreviations used in Figure 1.1, page 4

ATT	Access to Technologies (WHO)
BAC	Research on Bacterial Vaccines (WHO)
EXD	Executive Director
POP	Parasitic and Other Pathogens Vaccine Research (WHO)
PRD	Product Research and Development (WHO)
QSB	Quality Assurance and Safety: Biologicals (WHO)
VAM	Vaccines Assessment and Monitoring (WHO)
VIR	Research on Viral Vaccines (WHO)

Executive summary

Introduction

The Strategic Advisory Group of Experts (SAGE), established by the Director-General of WHO in 1999 to provide guidance on vaccines and biologicals, held its fourth annual meeting on 13 and 14 June 2002 at WHO headquarters, Geneva, Switzerland.

SAGE reviewed progress over the past year in relation to the objectives and targets set by the Department of Vaccines and Biologicals (V&B). Challenges, adjustments and refinements in priority setting and activities were discussed, and recommendations made in all key areas (see this section for the full text of the recommendations made by SAGE). SAGE plays an important global role in vaccines and immunization and its recommendations make an important impact at a time of change and challenge.

Main topics of discussion

The Strategic Plan

The V&B strategy for 2002–2005 represents a minor revision of the 2000–2003 Strategic Plan. The presentation to SAGE gave examples of changes in emphasis in the new plan with respect to five targets. Substantial revisions will be made in 2004. The review took into account progress, implementation and funding for work covered in the last plan as well as work being done which was not included in the last plan. In addition to the three priority targets on polio eradication, immunization safety, and new vaccine introduction, the new plan focuses on standardization and control of biologicals, and the supply and quality of vaccines - core functions considered to need independence from external funding. SAGE considered all nine targets through the individual subgroup sessions on innovation, the strengthening of immunization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30282

